source
- FDA pauses Regenxbio gene therapy trial for Hunter syndrome after spinal masses foundThe Food and Drug Administration has placed another hold on Regenxbio's gene-therapy trial for mucopolysaccharidosis type II, also known as Hunter syndrome, after new safety concerns emerged. Five…
- Pharma marketers urged to adopt share-of-answer strategy as AI use surges among physiciansPharma marketers are planning for 2027 as artificial intelligence reshapes how clinicians seek clinical answers. The rise of AI tools means that traditional metrics like share of voice and broad om…